Positive patient-reported outcomes data expand on the efficacy benefits of trastuzumab deruxtecan and pembrolizumab
Two studies show that quality of life was maintained or improved with new treatments for advanced breast cancer
The future of personalised risk-stratified breast cancer screening
Will widespread screening for breast cancer based on individual risk mean the end of the one-size-fits-all standard mammogram?
Optimising adjuvant treatment in HR+/HER2-negative early breast cancer
Gene-expression assays have produced a huge step forward in identifying patients who are likely to benefit from adjuvant chemotherapy but there is still a long way to go in the more specific targeting of treatment
Sibylle Loibl receives the ESMO Breast Cancer 2022 Award
In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer
Is molecular profiling useful in the management of breast cancer?
The value of genomic testing is being increasingly demonstrated and will evolve over time
Cancer care in war zones: what have we learnt?
In recent conflicts, good response to the health needs of refugees with cancer in receiving countries is consequence of an analysis of local cancer centres capacity and special measures to avoid fragmented care
Cancer Control Principles
Double standards in healthcare: a modern hypocrisy
Having treatment protocols for the rich countries and alternative protocols for the poor ones still nurtures global health disparities
Cancer Research
Age is ‘just a number’ - Not so in clinical trial enrollment
The new FDA guidance could be an important step toward necessary change to give adequate representation of older adults in cancer clinical trials
Perioperative survival after bilobectomy is worse than lobectomy
Although bilobectomy remains a valid procedure, comparatively high mortality rates indicate that cautious use and appropriate patient counselling is required
Encouraging safety data for the use of durvalumab after sequential chemotherapy in stage III unresectable NSCLC
Findings from the PACIFIC-6 trial echo the benefits seen with durvalumab after concomitant chemoradiotherapy, representing a potential alternative for vulnerable and older patients